N-[2-(dimethylamino)-5-[5-[2-(3-morpholin-4-ylanilino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-2-phenylacetamide

InChIKey	`JPCWMTOYDYYXLS-UHFFFAOYSA-N`
Compound Name	N-[2-(dimethylamino)-5-[5-[2-(3-morpholin-4-ylanilino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-2-phenylacetamide
Canonical SMILES	`CN(C)c1ccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)cc1NC(=O)Cc1ccccc1`
Clinical Status	Data-mined Candidate
Targets (Human+Pathogen)	7
Pfam Stratification	Cross-Family
Avg pChEMBL	6.43
Source	ChEMBL

2D Structure

Activity Profile

Target	Gene	Organism	Category	Pfam	pChEMBL	Type	Source
P35968	KDR	Homo sapiens	Human	PF07679 PF00047 PF13895 PF22971 PF07714 PF21339 PF17988 PF22854	6.9	Ki	ChEMBL
Q13188	STK3	Homo sapiens	Human	PF11629 PF00069	6.6	Ki	ChEMBL
Q7L7X3	TAOK1	Homo sapiens	Human	PF00069	6.6	Ki	ChEMBL
Q9Y4K4	MAP4K5	Homo sapiens	Human	PF00780 PF00069	6.4	Ki	ChEMBL
P07333	CSF1R	Homo sapiens	Human	PF00047 PF25305 PF07714	6.2	Ki	ChEMBL
P08069	IGF1R	Homo sapiens	Human	PF00757 PF07714 PF01030	6.2	Ki	ChEMBL
P22607	FGFR3	Homo sapiens	Human	PF21165 PF07679 PF13927 PF07714	6.1	Ki	ChEMBL